Gastrointestinal stromal tumour

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in the abdomen. They can occur at any age, the median age being 60-65 years, and typically cause bleeding, anaemia, and pain. GISTs have variable malignant potential, ranging from small lesions with a benign behaviour to fatal sarcomas. Most tumours stain positively for the mast/stem cell growth factor receptor KIT and anoctamin 1 and harbour a kinase-activating mutation in either KIT or PDGFRA. Tumours without such mutations could have alterations in genes of the succinate dehydrogenase complex or in BRAF, or rarely RAS family genes. About 60% of patients are cured by surgery. Adjuvant treatment with imatinib is recommended for patients with a substantial risk of recurrence, if the tumour has an imatinib-sensitive mutation. Tyrosine kinase inhibitors substantially improve survival in advanced disease, but secondary drug resistance is common.

[1]  C. Stratakis,et al.  Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. , 2007, The Journal of clinical endocrinology and metabolism.

[2]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[3]  E. Glatstein,et al.  Progression-free Survival in Gastrointestinal Stromal Tumours With High-dose Imatinib: Randomised Trial , 2006 .

[4]  J. Blay,et al.  Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing , 2011, PloS one.

[5]  C. Capella,et al.  Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa , 2001, Cancer.

[6]  G. Demetri,et al.  Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. D. Van den Abbeele,et al.  Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib , 2009, Pediatric blood & cancer.

[8]  Narasimhan P. Agaram,et al.  Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.

[9]  Robin L. Jones,et al.  Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  A. Krasinskas,et al.  “Seedling” Mesenchymal Tumors (Gastrointestinal Stromal Tumors and Leiomyomas) are Common Incidental Tumors of the Esophagogastric Junction , 2007, The American journal of surgical pathology.

[11]  B. Nilsson,et al.  Population‐based study of the diagnosis and treatment of gastrointestinal stromal tumours , 2006, The British journal of surgery.

[12]  B. Eisenberg,et al.  Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors , 2011, International Journal of Cancer.

[13]  F. Gleeson,et al.  The risks of radiation exposure related to diagnostic imaging and how to minimise them , 2011, BMJ : British Medical Journal.

[14]  A. Hartmann,et al.  Minute Gastric Sclerosing Stromal Tumors (GIST Tumorlets) Are Common in Adults and Frequently Show c-KIT Mutations , 2007, The American journal of surgical pathology.

[15]  S. George,et al.  Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors , 2013, Modern Pathology.

[16]  M. Nykter,et al.  Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors , 2011, Cancer.

[17]  W. Brugge,et al.  EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. , 2009, Gastrointestinal endoscopy.

[18]  M. Federico,et al.  Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study , 2007, BMC Cancer.

[19]  M. Heinrich,et al.  Gastrointestinal stromal tumour , 2007, The Lancet.

[20]  H. Joensuu,et al.  Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. , 2006, Gastroenterology.

[21]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[22]  Heikki Joensuu,et al.  Practical management of tyrosine kinase inhibitor-associated side effects in GIST. , 2011, Cancer treatment reviews.

[23]  Avijit Chakrabartty,et al.  Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.

[24]  Samuel Singer,et al.  PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.

[25]  J. Fletcher,et al.  Molecular and Clinicopathologic Characterization of Gastrointestinal Stromal Tumors (GISTs) of Small Size , 2010, The American journal of surgical pathology.

[26]  J. Fletcher,et al.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Lasota,et al.  Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.

[28]  H. Joensuu,et al.  Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. , 2011, European Journal of Surgical Oncology.

[29]  H. El‐Serag,et al.  The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000 , 2005, The American Journal of Gastroenterology.

[30]  T. Terada,et al.  The gastric hypercellular microleiomyoma as a precursor lesion for clinical gastrointestinal stromal tumors. , 1997, Human pathology.

[31]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[32]  K. S. Hall,et al.  Response to Imatinib Rechallenge of GIST That Recurs Following Completion of Adjuvant Imatinib Treatment - the First Analysis in the SSGXVIII/AIO Trial Patient Population , 2011 .

[33]  L. Brady,et al.  Radiotherapy in the treatment of gastrointestinal stromal tumor , 2011, Rare tumors.

[34]  倉本 正文,et al.  術後肝転移再発に対し imatinib mesylate (STI571) が奏効した胃 gastrointestinal stromal tumor の1例 , 2005 .

[35]  A. Kovatich,et al.  CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[36]  K. Ahrar,et al.  Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, American journal of clinical oncology.

[37]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Jejunum and Ileum: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 906 Cases Before Imatinib With Long-term Follow-up , 2006, The American journal of surgical pathology.

[38]  R. Schneider-Stock,et al.  High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Knuutila,et al.  DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. , 2000, Cancer research.

[40]  M. Heinrich,et al.  Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.

[41]  C. Ball,et al.  The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. , 2004, The American journal of pathology.

[42]  F. Grabellus,et al.  Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. , 2010, Transplantation proceedings.

[43]  S. Hirota,et al.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. , 2003, Gastroenterology.

[44]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Heldin,et al.  Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis. , 1991, The EMBO journal.

[46]  J. Fletcher,et al.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.

[47]  M. Brown,et al.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.

[48]  C. Antonescu,et al.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Nakajima,et al.  High incidence of microscopic gastrointestinal stromal tumors in the stomach. , 2006, Human pathology.

[50]  M. van de Rijn,et al.  Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Wei Zhang,et al.  A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.

[52]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[53]  J. Desai,et al.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Celestino,et al.  Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors , 2012, European Journal of Human Genetics.

[55]  S. Hirota,et al.  Absence of c‐kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients , 2004, The Journal of pathology.

[56]  I. Judson Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case , 2012, Clinical Cancer Research.

[57]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  L. Mariani,et al.  Natural History of Imatinib-naive GISTs: A Retrospective Analysis of 929 Cases With Long-term Follow-up and Development of a Survival Nomogram Based on Mitotic Index and Size as Continuous Variables , 2011, The American journal of surgical pathology.

[59]  J. Suo,et al.  Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. , 2012, World journal of gastroenterology.

[60]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[61]  P. Petrow,et al.  Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. , 2005, European journal of radiology.

[62]  Robert C. G. Martin,et al.  An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. , 2009, Archives of surgery.

[63]  E. van den Berg,et al.  Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Hirota,et al.  Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy , 2007, International Journal of Clinical Oncology.

[65]  E. Wardelmann,et al.  Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour , 2010, The British journal of surgery.

[66]  Se Jin Park,et al.  Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases. , 2012, Anticancer research.

[67]  E. Campo,et al.  Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[68]  J. Desai,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[69]  J. Blay,et al.  Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era , 2012, Clinical Cancer Research.

[70]  Wenmei Li,et al.  Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors. , 2012, World journal of gastroenterology.

[71]  Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  R. Sciot,et al.  Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors , 2011, Clinical Cancer Research.

[73]  C. Leutner,et al.  Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. , 2005, The Lancet. Oncology.

[74]  M. Heinrich,et al.  Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild‐type gastrointestinal stromal tumours: a comprehensive genotype–phenotype correlation study , 2012, Histopathology.

[75]  C. Mussi,et al.  Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  J. Fletcher,et al.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Blay,et al.  DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours , 2010, Histopathology.

[78]  K. Owzar,et al.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  H. Joensuu Risk stratification of patients diagnosed with gastrointestinal stromal tumor. , 2008, Human pathology.

[80]  J. Fletcher,et al.  KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications , 2004, The American journal of surgical pathology.

[81]  G. Demetri,et al.  Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132 , 2012, Annals of Surgical Oncology.

[82]  W. Kwan,et al.  Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. , 2006, World journal of gastroenterology.

[83]  D. Park,et al.  Current Trends in the Epidemiological and Pathological Characteristics of Gastrointestinal Stromal Tumors in Korea, 2003-2004 , 2010, Journal of Korean medical science.

[84]  J. Lasota,et al.  Histopathology of gastrointestinal stromal tumor , 2011, Journal of surgical oncology.

[85]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[86]  J. Blay,et al.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.

[87]  S. Hirota,et al.  Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. , 2000, The American journal of surgical pathology.

[88]  C. Antonescu,et al.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) , 2008, Cancer.

[89]  L. Lipton,et al.  Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase–deficient Gastrointestinal Stromal Tumors , 2013, The American journal of surgical pathology.

[90]  A. Odén,et al.  Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population , 1997, Cancer.

[91]  Joseph Schlessinger,et al.  Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor , 2007, Cell.

[92]  W. Young,et al.  Gastric Stromal Tumors in Carney Triad Are Different Clinically, Pathologically, and Behaviorally From Sporadic Gastric Gastrointestinal Stromal Tumors: Findings in 104 Cases , 2010, The American journal of surgical pathology.

[93]  A. Kuraishi,et al.  Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. , 2001, Gastroenterology.

[94]  C. Stratakis,et al.  Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. , 2002, American journal of medical genetics.

[95]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  L. Sobin,et al.  Gastrointestinal Stromal Tumors of the Stomach: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 1765 Cases With Long-term Follow-up , 2005, The American journal of surgical pathology.

[97]  S. Sheps,et al.  The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. , 1977, The New England journal of medicine.

[98]  E. Pilozzi,et al.  Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients , 2011, World journal of surgical oncology.

[99]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[100]  G. Mowatt,et al.  Systematic Review of Escalated Imatinib Doses Compared with Sunitinib or Best Supportive Care, for the Treatment of People with Unresectable/Metastatic Gastrointestinal Stromal Tumours Whose Disease has Progressed on the Standard Imatinib Dose , 2011, Journal of Gastrointestinal Cancer.

[101]  R. Yantiss,et al.  Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study , 2005, Modern Pathology.

[102]  L. Terracciano,et al.  Microscopic Gastrointestinal Stromal Tumors in Esophageal and Intestinal Surgical Resection Specimens: A Clinicopathologic, Immunohistochemical, and Molecular Study of 19 Lesions , 2008, The American journal of surgical pathology.

[103]  L. Bonomo,et al.  Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors : a systematic review ☆ , 2012 .

[104]  E. Wardelmann,et al.  Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Agaimy,et al.  Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients ≤40 years: an overview based on our case material and the literature , 2009, Langenbeck's Archives of Surgery.

[106]  M. Heinrich,et al.  “Pediatric-type” Gastrointestinal Stromal Tumors in Adults: Distinctive Histology Predicts Genotype and Clinical Behavior , 2011, The American journal of surgical pathology.

[107]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[108]  B. Eisenberg,et al.  Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST) , 2010, Annals of Surgical Oncology.

[109]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[110]  C. Antonescu,et al.  Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. , 2010 .

[111]  E. Wardelmann,et al.  Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.

[112]  P. Terrier,et al.  PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. , 2004, Gastroenterology.

[113]  L. Mazzucchelli,et al.  KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.

[114]  C. Antonescu,et al.  Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.

[115]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[117]  J. Blay,et al.  Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.

[118]  E. Wardelmann,et al.  Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  M. Fukayama,et al.  Gastrointestinal Stromal Tumors of Neurofibromatosis Type I (von Recklinghausen's Disease) , 2005, The American journal of surgical pathology.

[120]  E. Wiemer,et al.  A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients , 2012, Clinical Cancer Research.

[121]  C. Antonescu,et al.  Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.

[122]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[123]  Z. Hall Cancer , 1906, The Hospital.

[124]  N. Socci,et al.  SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors , 2012, BMC Cancer.

[125]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[126]  G. Demetri,et al.  Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  J. Blay,et al.  Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[129]  S. Hirota,et al.  Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.

[130]  S. Hirota,et al.  Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[131]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[132]  C. Antonescu,et al.  Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor , 2007, Annals of surgery.

[133]  J. Lee,et al.  Primary leiomyosarcomas of the gastrointestinal tract in the post-gastrointestinal stromal tumor era. , 2012, Annals of diagnostic pathology.